ClinicalTrials.gg
RecruitingNCT07760142Updated Aug 18, 2026

Multichannel Neuromuscular Electrical Stimulation With Core Exercise for Chronic Low Back Pain

An interventional study of Core exercise program and StimaWELL 120MTRS - lumbar strengthening program in Chronic Low-back Pain, sponsored by Uskudar University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by Uskudar University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

Chronic non-specific low back pain is a common musculoskeletal condition that can adversely affect daily activities, functional capacity, sleep, and quality of life. Exercise therapy is a key component of conservative management, and core exercises are used to improve trunk control and the coordinated function of the abdominal, lumbar, and pelvic musculature. Neuromuscular electrical stimulation may be added to exercise to facilitate muscle activation and support pain management; however, the additional clinical benefit of different multichannel stimulation programs remains uncertain.

This three-arm randomized controlled trial evaluates the effects of two multichannel neuromuscular electrical stimulation programs added to a standardized core exercise program in adults with chronic non-specific low back pain. Forty-five participants are allocated in a 1:1:1 ratio to (1) core exercise plus a lumbar strengthening stimulation program, (2) core exercise plus a muscle relaxation stimulation program, or (3) core exercise alone. Treatment is delivered twice weekly for six weeks (12 sessions). In the two stimulation groups, StimaWELL 120MTRS therapy is applied for 30 minutes at 40 °C. Outcomes are assessed at baseline and at week 6. The primary outcome is low back pain intensity measured with a 100-mm Visual Analog Scale. Secondary outcomes are disability, patient-specific functional status, quality of life, and insomnia severity.

Read the detailed description

Design and setting This is a prospective, three-arm, parallel-group, assessor-blinded randomized controlled trial conducted at the Semiha Atas Timurtas Private Health Professional Services Unit in Cizre, Sirnak, Turkey. Institutional permission for the study site has been obtained.

Participants Adults aged 18-55 years with chronic non-specific low back pain lasting at least three months are screened for eligibility. Eligible participants provide written informed consent before study procedures.

Randomization and masking Participants are randomized in a 1:1:1 ratio to one of three treatment groups. Participants and the treating physiotherapist cannot be blinded because of the nature of the interventions. Outcome assessments are performed by a physiotherapist who is unaware of group allocation. [DOLDURULACAK - random sequence generation and allocation concealment method, if available.]

Interventions All groups receive the same standardized core exercise program for six weeks, two sessions per week (12 sessions total). [DOLDURULACAK - exact core exercises, sets/repetitions, session duration, and progression criteria.] Group 1 additionally receives the StimaWELL 120MTRS lumbar strengthening program for 30 minutes at 40 °C during each treatment session.

Group 2 additionally receives the StimaWELL 120MTRS muscle relaxation program for 30 minutes at 40 °C during each treatment session.

Group 3 receives the core exercise program alone and does not receive StimaWELL 120MTRS treatment.

Outcome assessment Assessments are conducted before treatment (baseline/week 0) and after completion of the six-week program (week 6). Low back pain intensity is measured with a 100-mm Visual Analog Scale. Secondary outcomes include the Oswestry Disability Index, Patient-Specific Functional Scale, WHOQOL-BREF Turkish version, and Insomnia Severity Index.

Statistical analysis The planned sample size is 45 participants (15 per group). The sample-size calculation used G*Power 3.1.9 with an effect size of 0.25, alpha of 0.05, and power of 0.80, yielding a minimum required sample of 42; the target was increased to 45 to permit equal allocation. Group, time, and group-by-time interaction will be evaluated using a two-way mixed-design analysis of variance, with statistical significance set at p \< 0.05.

02

Conditions studied

  • Chronic Low-back Pain

Browse trials for

Keywords

  • neuromuscular electrical stimulation
03

In context

Low Back Pain

2,922 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

This study's planned enrollment of 45 is below the median of 60 across 2,364 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Uskudar University is the lead sponsor of 170 studies on the registry; 36 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 to 55 years.
  • Chronic non-specific low back pain lasting at least three months.
  • Low back pain not attributable to a specific trauma, infection, tumor, fracture, rheumatologic disease, or serious neurological disorder.
  • Pain intensity meeting the protocol threshold stated as VAS >=3. [TEYIT - because the outcome VAS is a 100-mm scale, clarify whether the intended eligibility threshold is >=30 mm (equivalent to 3/10) rather than >=3 mm.]
  • Physical and cognitive ability to perform the core exercise program.
  • Willingness to attend two treatment sessions per week for six weeks (12 sessions total).
  • Voluntary participation and provision of written .

Exclusion criteria

Exclusion Criteria:

  • Age younger than 18 years or older than 55 years.
  • Low back pain due to disc herniation, spinal stenosis, fracture, tumor, infection, or inflammatory disease.
  • Nerve root involvement, marked sensory loss, or muscle weakness.
  • Previous lumbar spine surgery.
  • Pacemaker or other electronic implant; pregnancy; epilepsy; or active cancer.
  • Open wound or skin disease in the treatment area.
  • Physical therapy for low back pain within the previous month or continuation of another low back pain treatment during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Core Exercise + Multichannel NMES Lumbar Strengthening

    Participants receive the standardized core exercise program plus the StimaWELL 120MTRS lumbar strengthening program. Treatment is delivered twice weekly for six weeks (12 sessions). The device program is applied for 30 minutes at 40 °C during each treatment session.

    Other: Core exercise program · Device: StimaWELL 120MTRS - lumbar strengthening program

  • Experimental
    Core Exercise + Multichannel NMES Muscle Relaxation

    Participants receive the standardized core exercise program plus the StimaWELL 120MTRS muscle relaxation program. Treatment is delivered twice weekly for six weeks (12 sessions). The device program is applied for 30 minutes at 40 °C during each treatment session.

    Other: Core exercise program · Device: StimaWELL 120MTRS - muscle relaxation program

  • Active comparator
    Core Exercise Alone

    Participants receive only the standardized core exercise program, identical to the core exercise program used in the other two groups, twice weekly for six weeks (12 sessions). No StimaWELL 120MTRS treatment is administered.

    Other: Core exercise program

Interventions

  • OtherCore exercise program

    Core Exercise + Multichannel NMES Lumbar Strengthening; Core Exercise + Multichannel NMES Muscle Relaxation; Core Exercise Alone

    Also known as: A standardized supervised core exercise program delivered twice weekly for six weeks (12 sessions), identical in all three study arms

  • DeviceStimaWELL 120MTRS - lumbar strengthening program

    Multichannel neuromuscular electrical stimulation using the StimaWELL 120MTRS lumbar strengthening program, applied for 30 minutes at 40 °C, twice weekly for six weeks (12 sessions), in addition to the core exercise program.

  • DeviceStimaWELL 120MTRS - muscle relaxation program

    Multichannel neuromuscular electrical stimulation using the StimaWELL 120MTRS muscle relaxation program, applied for 30 minutes at 40 °C, twice weekly for six weeks (12 sessions), in addition to the core exercise program.

06

What researchers measure

Primary outcomes

  1. Change in low back pain intensity (100-mm Visual Analog Scale)

    Low back pain intensity is assessed using a 100-mm horizontal Visual Analog Scale. Participants mark the point that best represents their average low back pain during the previous seven days, anchored by 0 mm (no pain) and 100 mm (unbearable pain). The distance from the 0-mm anchor to the mark is measured in millimeters. Higher values indicate greater pain intensity.

    Time frame: Baseline (week 0) and at the end of the six-week treatment program (week 6)

07

Study locations

1 of 1 sites recruiting
  • Semiha Atas Timurtas Private Health Professional Services Unit
    Şırnak, Turkey (Türkiye)
    Recruiting
    • Semiha Ataş Timurtaş · Contact+90 542 648 16 08
08

References and documents

Publications

  • Fortin M, Wolfe D, Dover G, Boily M. The effect of phasic versus combined neuromuscular electrical stimulation using the StimaWELL 120MTRS system on multifidus muscle morphology and function in patients with chronic low back pain: a randomized controlled trial protocol. BMC Musculoskelet Disord. 2022 Jul 1;23(1):627. doi: 10.1186/s12891-022-05578-1. PubMed 35773711 ↗
  • Wolfe D, Dover G, Boily M, Fortin M. The Immediate Effect of a Single Treatment of Neuromuscular Electrical Stimulation with the StimaWELL 120MTRS System on Multifidus Stiffness in Patients with Chronic Low Back Pain. Diagnostics (Basel). 2024 Nov 19;14(22):2594. doi: 10.3390/diagnostics14222594. PubMed 39594260 ↗
  • Frizziero A, Pellizzon G, Vittadini F, Bigliardi D, Costantino C. Efficacy of Core Stability in Non-Specific Chronic Low Back Pain. J Funct Morphol Kinesiol. 2021 Apr 22;6(2):37. doi: 10.3390/jfmk6020037. PubMed 33922389 ↗
  • Alrwaily M, Schneider M, Sowa G, Timko M, Whitney SL, Delitto A. Stabilization exercises combined with neuromuscular electrical stimulation for patients with chronic low back pain: a randomized controlled trial. Braz J Phys Ther. 2019 Nov-Dec;23(6):506-515. doi: 10.1016/j.bjpt.2018.10.003. Epub 2018 Oct 18. PubMed 30482602 ↗

Individual participant data

Plan to share: No — Individual participant data are not planned to be shared publicly

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07760142
Lead sponsor
Uskudar University
Responsible party
Doç.Dr.Ömer Şevgin (Associate Professor, Uskudar University) — Principal investigator
First posted
Aug 12, 2026
Start date
Aug 14, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 18, 2026

Study contacts

ömer şevgin
Contact
omer.sevgin@uskudar.edu.tr
+905069787535
Semiha Ataş Timurtaş
study chair · Üsküdar University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion